AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7899366
Drug: Pefloxacin 400
RxNorm normalized name: pefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin 400 mg once-a-week (group A: n = 185)
Trial: 7899366
Drug: Pefloxacin 400
RxNorm normalized name: pefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin 400 mg once-a-month (group B: n = 176)
Trial: 7899366
Drug: Pefloxacin 400
RxNorm normalized name: pefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin 400 mg once-a-week (group A)
Trial: 7899366
Drug: Pefloxacin 400
RxNorm normalized name: pefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin 400 mg once-a-month (group B)
Trial: 2526830
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous and intracoronary streptokinase without immediate coronary angioplasty (Group I)
Trial: 2526830
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous and intracoronary streptokinase with immediate coronary angioplasty (Group II)
Trial: 28501062
Drug: Systemic Propolis
RxNorm normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic Propolis as an adjuvant to nonsurgical periodontal treatment
Trial: 26153173
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg propranolol, 2 hours before surgery
Trial: 26153173
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 15 mg ketamine and 50 µg fentanyl, 5 min before surgery
Trial: 16368752
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment (2 IU/m2)
Trial: 9032099
Drug: Troglitazone 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 800 mg q.d.
Trial: 22711185
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of EMLA
Trial: 22711185
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg diclofenac suppository
Trial: 22711185
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of petrolatum ointment
Trial: 15030456
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir 3 g daily from engraftment to day 84
Trial: 15030456
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir 5 mg/kg three times weekly from engraftment to day 84
Trial: 11473677
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled corticosteroids (CS)
Trial: 9433395
Drug: Urinary or
RxNorm normalized name: INVESTIGATIONAL ANTI-NEOPLASTIC DRUGS GENITOURINARY ORGANS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary or recombinant human follicle stimulating hormone (FSH) treatment
Trial: 26590950
Drug: Extended-release-plus-immediate-release bilayer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release-plus-immediate-release bilayer tablet (Test)
Trial: 26590950
Drug: Gastro-resistant delayed-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastro-resistant delayed-release tablet (Reference)
Trial: 24980811
Drug: Moxifloxacin-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin-based triple therapy (MML): moxifloxacin 400 mg/day, metronidazole 500 mg b.i.d., lansoprazole 30 mg b.i.d. for 10 days
Trial: 24980811
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (AL-CML): amoxicillin 1 g b.i.d. and lansoprazole 30 mg b.i.d. for the first 5 days, followed by clarithromycin 500 mg b.i.d., metronidazole 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for the second 5 days
Trial: 24980811
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (CAL): amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for 14 days
Trial: 21999231
Drug: CHO‐rFVIIa (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO‐rFVIIa (90 μg/kg for healthy subjects; 270 μg/kg for patients)
Trial: 21999231
Drug: BHK‐rFVIIa (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BHK‐rFVIIa (90 μg/kg for healthy subjects; 270 μg/kg for patients)
Trial: 18672762
Drug: Compound Paeonol
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Paeonol Dripping Pill (CPDP)
Trial: 18672762
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western therapy (Group A)
Trial: 16896051
Drug: Vitamin/mineral combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin/mineral combination (factor A: retinol and zinc; factor B: riboflavin and niacin; factor C: ascorbic acid and molybdenum; factor D: beta-carotene, alpha-tocopherol, and selenium)
Trial: 12795457
Drug: Omeprazole +
RxNorm normalized name: Omeprazole + SyrSpend SF Alka
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole + Amoxicillin + Clarithromycin (OAC-L) for 1 week
Trial: 12795457
Drug: Omeprazole +
RxNorm normalized name: Omeprazole + SyrSpend SF Alka
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole + Amoxicillin + Clarithromycin (OAC-H) for 1 week
Trial: 11035891
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol administered 1 day after mifepristone
Trial: 11035891
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol administered 2 days after mifepristone
Trial: 11035891
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol administered 3 days after mifepristone
Trial: 19156626
Drug: Acarbose (alpha-glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (alpha-glucosidase inhibitor)
Trial: 8776746
Drug: Brofaromine (CGP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brofaromine (CGP 11,305 A), a selective and reversible MAO A inhibitor
Trial: 6376292
Drug: Tripotassium dicitrato
RxNorm normalized name: Tripotassium dicitratobismuthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripotassium dicitrato bismuthate (TDB) tablet four times a day
Trial: 6376292
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cimetidine (1.6 g daily)
Trial: 6376292
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cimetidine after crossover
Trial: 14556543
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg per day for 8 weeks
Trial: 16923435
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (n = 199) received optimized nonpharmacological and pharmacological cardiovascular treatments by a geriatrician according to guidelines.
Trial: 24170758
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for adherence and depression (CBT-AD)
Trial: 22038792
Drug: Tamsulosin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.2 mg) once daily
Trial: 20386475
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g arginine + 300 mg grape seed extract
Trial: 20386475
Drug: 3.0 g
RxNorm normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g arginine + 300 mg grape seed extract
Trial: 15963082
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg twice daily plus famotidine 20 mg twice daily
Trial: 12908901
Drug: Supplemental intakes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental intakes of 0.3, 1.0 and 2.0 g EPA+DHA/d
Trial: 12908901
Drug: Antioxidant co-supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant co-supplementation (200 microg Se, 3 mg Mn, 30 mg D-alpha-tocopheryl succinate, 90 mg ascorbic acid, 450 microg vitamin A)
Trial: 1865542
Drug: E5 murine
RxNorm normalized name: Murine Ear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5 murine monoclonal antibody (2 mg/kg)
Trial: 31727667
Drug: Choosing Wisely
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choosing Wisely Australia 5 Questions resource and preparation video
Trial: 31727667
Drug: Preparation video
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation video
Trial: 23799810
Drug: Active reference
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active reference treatment
Trial: 18437790
Drug: Immediate or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate or early loaded implants
Trial: 15134615
Drug: TNF-alpha inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF-alpha inhibitors (etanercept and infliximab)
Trial: 15134615
Drug: No TNF-alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No TNF-alpha inhibition therapy (Control Group 2)
Trial: 12351257
Drug: 4% modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% modified gelatin (GEL)
Trial: 12351257
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution (RL)
Trial: 9647031
Drug: Glutamine 4
RxNorm normalized name: glutamine 475 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine 4 g/day
Trial: 9647031
Drug: Glutamine 8
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine 8 g/day
Trial: 7807504
Drug: Quinapril (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (10-40 mg twice daily) in Study I; titrated every 1-2 weeks for 6 weeks, followed by 6 weeks of therapy.
Trial: 7807504
Drug: Quinapril (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (5-20 mg twice daily) in Study II; titrated every 4 weeks for 16 weeks, followed by a 12-week maintenance period.
Trial: 790553
Drug: Ketoprofen 150
RxNorm normalized name: ketoprofen 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 150 mg daily
Trial: 19318694
Drug: Dexlansoprazole MR
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole MR 120 mg
Trial: 16428050
Drug: Single-phase contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-phase contrast medium injection (Group 1)
Trial: 16428050
Drug: Dual-phase contrast
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-phase contrast medium injection (Group 2)
Trial: 16428050
Drug: Three-phase injection
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-phase injection (Group 3)
Trial: 8884561
Drug: Diazoxide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide (150 mg)
Trial: 9532986
Drug: Acyclovir 200
RxNorm normalized name: acyclovir 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 200 mg four times a day
Trial: 30079863
Drug: Nicotine preloading
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine preloading with a 21 mg/24 hour nicotine patch for 4 weeks prior to quit date
Trial: 27197192
Drug: Trastuzumab and
RxNorm normalized name: pertuzumab and trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab and chemotherapy
Trial: 22290743
Drug: Rivastigmine (4.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (4.6 mg/24 hours for 3 weeks)
Trial: 19020639
Drug: Placebo (balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (balanced saline solution, 1 drop given preoperatively)
Trial: 16363755
Drug: Transvaginal Sacrospinous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transvaginal Sacrospinous Uterine Suspension (SSUS)
Trial: 8577211
Drug: Metformin after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin after low protein breakfast
Trial: 8577211
Drug: Metformin after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin after low fat breakfast
Trial: 8577211
Drug: Metformin after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin after low carbohydrate breakfast
Trial: 8577211
Drug: Metformin after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin after standard breakfast
Trial: 2251616
Drug: Bromocriptine (Parlodel;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (Parlodel; Sandoz) in doses up to 26 mg daily
Trial: 2251616
Drug: Bromocriptine (Parlodel;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (Parlodel; Sandoz) in doses beyond 25-30 mg daily
Trial: 2251616
Drug: Bromocriptine (Parlodel;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (Parlodel; Sandoz) with slow dose increases
Trial: 425546
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no considerable treatment)
Trial: 31575021
Drug: Oral Vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Vitamin A&D supplement (20,000 IU retinyl palmitate and 2000 IU cholecalciferol)
Trial: 29878061
Drug: HMBF (0.81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMBF (0.81 kcal/mL)
Trial: 29878061
Drug: BMBF (0.72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMBF (0.72 kcal/mL)
Trial: 26881417
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with daily feedback
Trial: 26881417
Drug: Lottery incentive
RxNorm normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [BEACH DREAM GLITTERY SUNSCREEN SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lottery incentive (daily eligibility for approximately $1.40 if goal achieved)
Trial: 26881417
Drug: Loss incentive
RxNorm normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loss incentive ($42 allocated monthly upfront, $1.40 removed for each day the goal is not achieved)
Trial: 25222630
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation and multi-family group treatment (CR-MFG)
Trial: 20797407
Drug: Intravenous micafungin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous micafungin (MCFG) 150-300 mg once daily
Trial: 20797407
Drug: Intravenous voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous voriconazole (VRCZ) 6 mg/kg twice on Day 1 followed by 4 mg/kg twice daily
Trial: 11867369
Drug: IV tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tramadol (150‐mg bolus followed by infusion, total 450 mg/24 h)
Trial: 11867369
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (2 mg, then 0.2 mg/h)
Trial: 7593870
Drug: Individualized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized cognitive treatment (CT)
Trial: 1958108
Drug: ivermectin 100
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ivermectin 100 mcg/kg
Trial: 1796228
Drug: DEC 3
RxNorm normalized name: Zodryl DEC 35 Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC 3 mg/kg
Trial: 1958108
Drug: ivermectin 100
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ivermectin 100 mcg/kg or DEC 3 mg/kg (2 successive doses)
Trial: 1958108
Drug: ivermectin 100
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ivermectin 100 mcg/kg or DEC 3 mg/kg
Trial: 6211296
Drug: sulfinpyrazone, 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulfinpyrazone, 800 mg/day
Trial: 22157240
Drug: Probiotic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic mixture (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium longum, and Streptococcus thermophilus 1.0×10 CFU) taken daily for 8 weeks
Trial: 16036193
Drug: Intraperitoneal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal infusion of a mixture of 10 mL of 0.5% bupivacaine (50 mg) with epinephrine (1:500) in 40 mL of Ringer's lactate solution postoperatively (Group A)
Trial: 16036193
Drug: The same
RxNorm normalized name: This Is The Same Medication Label
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The same mixture solution infusion preoperatively and postoperatively (total 100 mg bupivacaine) (Group B)
Trial: 10825867
Drug: Opalescence (10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opalescence (10% carbamide peroxide gel)
Trial: 10825867
Drug: NiteWhite Excel
RxNorm normalized name: chlorhexidine diacetate Topical Ointment [Excel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NiteWhite Excel (10% carbamide peroxide gel)
Trial: 7578781
Drug: Fixed bridge
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed bridge between the distal tooth of the residual dentition and an implant
Trial: 7578781
Drug: Free-standing bridge
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free-standing bridge on 2 implants
Trial: 7578781
Drug: Implant-supported bridges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported bridges
Trial: 7578781
Drug: Tooth-implant fixed
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth-implant fixed bridges
Trial: 2154154
Drug: Jet nebulizer
RxNorm normalized name: Pari LC Jet Nebulizer Plus RE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet nebulizer (1.75 ml, 1,750 micrograms of radiolabeled fenoterol solution)
Trial: 6814282
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy with two timothy major allergens, 19, 25, or partially purified timothy extract
Trial: 31438986
Drug: Tocilizumab 12
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab 12 mg/kg IV every 2 weeks (Q2W)
Trial: 1961665
Drug: Caffeine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 2.5 mg/kg
Trial: 1961665
Drug: Caffeine 5.0
RxNorm normalized name: CAFFEINE 5.0 mg in 1000 mL TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 5.0 mg/kg
Trial: 23720124
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection with local corticosteroids
Trial: 21540198
Drug: Canakinumab 100
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab 100 mg
Trial: 21540198
Drug: Canakinumab 200
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab 200 mg
Trial: 21540198
Drug: Canakinumab (50+50+25+25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (50+50+25+25 mg)
Trial: 2606428
Drug: Colchicine 0.5
RxNorm normalized name: colchicine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg
Trial: 22507493
Drug: Low-dose abdominal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose abdominal computed tomography (LDCT)
Trial: 15205246
Drug: Brimonidine purite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine purite 0.15% given twice daily
Trial: 15205246
Drug: Dorzolamide 2%
RxNorm normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide 2% given twice daily
Trial: 11087239
Drug: Doxazosin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin administration (subgroup 1B, n = 7)
Trial: 11087239
Drug: No doxazosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No doxazosin administration (subgroup 1A, n = 7)
Trial: 8922160
Drug: Heparin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin infusion for 12 to 18 hours after intervention
Trial: 8922160
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin infusion